Mittal Suneeta, Agarwal Sonika, Kumar Sunesh, Batra Ashima
Department of Obstetrics & Gynecology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110-029, India.
Indian J Med Res. 2005 Aug;122(2):132-6.
BACKGROUND & OBJECTIVE: Medical abortion though legalized in India, is still not very popular. A disadvantage of medical abortion is the longer duration of bleeding compared with surgical abortion which may reduce acceptability. Due consideration needs to be given to the issues related to medical abortion for improving the reproductive health status of women suffering from consequences of unsafe and illegal surgical abortion. The present study compared the efficacy of oral and vaginal administration of misoprostol after a single dose of 200 mg of mifepristone and evaluated the influence of continuing misoprostol for one week on efficacy and side effects.
A double-blind randomized controlled trial with 150 healthy pregnant women requesting medical abortion with < 63 days of amenorrhoea was conducted in the gynecological and family planning clinic at All India Institute of Medical Sciences, New Delhi. Mifepristone (200 mg) was administered orally on day one, followed by 0.8 mg misoprostol either orally or vaginally on day three. Women in the oral group and one of the two vaginal groups continued 0.4 mg of oral misoprostol twice daily for seven days.
Complete abortion rate in each of the groups was 96-100 per cent. The addition of misoprostol 0.4 mg twice a day from day 4-10 did not help in increasing successful outcome or shortening of duration or amount of bleeding.
INTERPRETATION & CONCLUSION: Medical abortion for pregnancy up to 63 days using misoprostol 0.8 mg vaginal/oral after pretreatment with mifepristone 200 mg is a safe and successful procedure. No differences in efficacy or duration of bleeding were observed with addition of oral misoprostol for 1 wk after abortion.
药物流产在印度虽已合法化,但仍不太普及。与手术流产相比,药物流产的一个缺点是出血时间较长,这可能会降低其可接受性。为改善因不安全和非法手术流产后果而受苦的妇女的生殖健康状况,需要充分考虑与药物流产相关的问题。本研究比较了单次服用200毫克米非司酮后口服和阴道给予米索前列醇的疗效,并评估了持续服用米索前列醇一周对疗效和副作用的影响。
在新德里全印度医学科学研究所的妇科和计划生育诊所,对150名停经<63天、要求进行药物流产的健康孕妇进行了一项双盲随机对照试验。第1天口服米非司酮(200毫克),第3天口服或阴道给予0.8毫克米索前列醇。口服组和两个阴道组之一的妇女从第4天至第10天每天两次继续口服0.4毫克米索前列醇,持续7天。
每组的完全流产率均为96%-100%。从第4天至第10天每天两次添加0.4毫克米索前列醇无助于提高成功结局或缩短出血持续时间或出血量。
在200毫克米非司酮预处理后,使用0.8毫克米索前列醇经阴道/口服进行妊娠63天以内的药物流产是一种安全且成功的方法。流产后添加口服米索前列醇1周,在疗效或出血持续时间方面未观察到差异。